These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 7272219)

  • 1. Kinetics of elimination of antithrombin III concentrate in heparinized patients.
    Marciniak E; Gockerman JP
    Br J Haematol; 1981 Aug; 48(4):617-25. PubMed ID: 7272219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies of the heterogeneity of antithrombin III concentrates.
    Barrowcliffe TW; Eggleton CA; Mahmoud M
    Br J Haematol; 1983 Sep; 55(1):37-46. PubMed ID: 6882687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparin-antithrombin III binding. In vitro and in vivo studies.
    Chan V; Chan TK
    Haemostasis; 1979; 8(6):373-89. PubMed ID: 511016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of congenital antithrombin III deficiency with concentrates.
    Mannucci PM; Boyer C; Wolf M; Tripodi A; Larrieu MJ
    Br J Haematol; 1982 Mar; 50(3):531-5. PubMed ID: 7066204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Alteration in coagulation and fibrinolysis after burn injury and significance of anticoagulation therapy using heparin and antithrombin III concentrate].
    Ono I
    Hokkaido Igaku Zasshi; 1987 Jan; 62(1):108-21. PubMed ID: 3817736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antithrombin III concentrate: its catabolism in health and in antithrombin III deficiency.
    Tengborn L; Frohm B; Nilsson LE; Nilsson IM
    Scand J Clin Lab Invest; 1981 Sep; 41(5):469-77. PubMed ID: 7031840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Catabolism and distribution of functionally heterogeneous human antithrombin III.
    Marciniak E; Romond EH
    J Lab Clin Med; 1987 Jan; 109(1):89-96. PubMed ID: 3794520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Study of serum level of antithrombin-III antigen, antithrombin activity, and its ratio of AT-III-heparin complex formation in maintenance hemodialysis patients].
    Yoshida K; Saka M; Kaneko Y; Kubota K; Hirao Y; Okajima E; Ishida M; Kihouin K; Motomiya Y
    Nihon Jinzo Gakkai Shi; 1989 Nov; 31(11):1171-7. PubMed ID: 2625740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Purification and characterization of hereditary abnormal antithrombin III with impaired thrombin binding.
    Jørgensen M; Petersen LC; Thorsen S
    J Lab Clin Med; 1984 Aug; 104(2):245-56. PubMed ID: 6747440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antithrombin III deficiency: decreased synthesis of a biochemically normal molecule.
    Ambruso DR; Leonard BD; Bies RD; Jacobson L; Hathaway WE; Reeve EB
    Blood; 1982 Jul; 60(1):78-83. PubMed ID: 7082848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. S protein modulates the heparin-catalyzed inhibition of thrombin by antithrombin III. Evidence for a direct interaction of S protein with heparin.
    Preissner KT; Müller-Berghaus G
    Eur J Biochem; 1986 May; 156(3):645-50. PubMed ID: 3699029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elimination of intravenously administered radiolabelled antithrombin III and heparin in humans.
    de Swart CA; Nijmeyer B; Andersson LO; Holmer E; Sixma JJ; Bouma BN
    Thromb Haemost; 1984 Aug; 52(1):66-70. PubMed ID: 6495266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pasteurisation induced changes in an antithrombin III concentrate.
    Winkelman L; Haddon ME
    Thromb Res; 1986 Jul; 43(2):219-27. PubMed ID: 3738862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous nitroglycerin-induced heparin resistance: a qualitative antithrombin III abnormality.
    Becker RC; Corrao JM; Bovill EG; Gore JM; Baker SP; Miller ML; Lucas FV; Alpert JA
    Am Heart J; 1990 Jun; 119(6):1254-61. PubMed ID: 2112878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new familial variant of antithrombin III: 'antithrombin III Paris'.
    Wolf M; Boyer C; Lavergne JM; Larrieu MJ
    Br J Haematol; 1982 Jun; 51(2):285-95. PubMed ID: 7082587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Covalent complexes between low molecular weight heparin fragments and antithrombin III - inhibition kinetics and turnover parameters.
    Hoylaerts M; Holmer E; de Mol M; Collen D
    Thromb Haemost; 1983 Apr; 49(2):109-15. PubMed ID: 6868006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombin III Northwick Park: demonstration of an inactive high MW complex with increased affinity for heparin.
    Lane DA; Flynn A; Ireland H; Erdjument H; Samson D; Howarth D; Thompson E
    Br J Haematol; 1987 Apr; 65(4):451-6. PubMed ID: 3580302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The in vitro effects of antithrombin III on the activated coagulation time in patients on heparin therapy.
    Levy JH; Montes F; Szlam F; Hillyer CD
    Anesth Analg; 2000 May; 90(5):1076-9. PubMed ID: 10781455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneity of the "classical" antithrombin III deficiency.
    Sas G; Petö I; Bánhegyi D; Blaskó G; Domján G
    Thromb Haemost; 1980 Jun; 43(2):133-6. PubMed ID: 7455972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies of heparin binding to antithrombin III by crossed immunoelectrophoresis.
    Barrowcliffe TW
    Thromb Haemost; 1980 Feb; 42(5):1434-45. PubMed ID: 7368150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.